

May 11, 1999

To the FDA

I have recently been informed that the FDA drafted a memorandum of understanding intended to provide legislative guidance to state agencies as a part of the FDA Modernization Act of 1997, the FDA drafted section 503A which governs the practice of pharmacy compounding.

I am a consumer who regularly uses compounded drugs that are interstate distributed. Over the years I have used several types of non-compounded drugs for a problem I have. The results were toxic reactions. Compounded drugs have made a big difference in the quality of my life.

As a healthcare consumer, there should be no restrictions to the delivery of a compounded medication prescribed for me regardless of where I may live or travel.

In its present form MDA, as

98N-1265

C 2259

well as the Compounding section 503a of the Modernization Act, severely restricts the rights of physicians and patients to obtain healthcare from the provider of their choice and infringes on the rights of compounding pharmacists to serve the public's medical needs

I sincerely hope that the M&U as well as the compounding sections 503a of the Modernization Act will be amended no later than May 27, 1999

Doris Naldi

Doris Naldi  
3955 E. Lake Hernando Ln.  
Hernando, FL 34442



Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, Md 20857-0003

202574993